search
Back to results

Phenotyping Mitochondrial and Immune Dysfunction in POTS With Targeted Clinical Intervention.

Primary Purpose

Postural Tachycardia Syndrome

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Time restricted eating
Sponsored by
University of California, San Diego
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Postural Tachycardia Syndrome focused on measuring Time-Restricted Eating, Intermittent fasting, POTS, Postural Tachycardia Syndrome

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age: 18-70 years old
  2. BMI < 40 kg/m2 AND
  3. POTS, as defined by the presence of any of the following criteria:

    • For patients age 20 or older, increase in heart rate ≥ 30 bpm within ten minutes of upright posture (tilt test or standing) from a supine position (For patients age 18-19, heart rate increase must be >40 bpm)
    • Associated with related symptoms that are worse with upright posture and that improve with recumbency
    • Chronic symptoms that have lasted for longer than six months
    • In the absence of other disorders, medications, or functional states that are known to predispose to orthostatic tachycardia
  4. Baseline eating period > 12-hour window

    Exclusion Criteria:

  5. Taking insulin within the last 6 months.
  6. Manifest diabetes, defined as HbA1c > 7.0% given a 0.3% margin of error in lab readings, or diagnosis of diabetes.
  7. Known inflammatory and/or rheumatologic disease.
  8. Active tobacco abuse or illicit drug use or history of treatment for alcohol abuse.
  9. Pregnant or breast-feeding women.
  10. Shift workers with variable (e.g. nocturnal) hours.
  11. Caregivers for dependents requiring frequent nocturnal care/sleep interruptions.
  12. Planned travel to a time zone with greater than a 3-hour difference during study period.
  13. History of a major adverse cardiovascular event within the past 1 year (acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA)).
  14. Uncontrolled arrhythmia (i.e. rate-controlled atrial fibrillation/atrial flutter are not exclusion criteria).
  15. History of thyroid disease requiring dose titration of thyroid replacement medication(s) within the past 3 months (i.e. hypothyroidism on a stable dose of thyroid replacement therapy is not an exclusion).
  16. History of adrenal disease.
  17. History of malignancy undergoing active treatment, except non-melanoma skin cancer.
  18. Known history of type I diabetes.
  19. History of eating disorder.
  20. History of cirrhosis.
  21. History of stage 4 or 5 chronic kidney disease or requiring dialysis.
  22. History of HIV/AIDS.
  23. Currently enrolled in a weight-loss or weight-management program.
  24. On a special or prescribed diet for other reasons (e.g. Celiac disease).
  25. Currently taking any medication that is meant for, or has known effect on, appetite.
  26. Any history of surgical intervention for weight management.
  27. Uncontrolled psychiatric disorder (including history of hospitalization for psychiatric illness).
  28. A score of >16 on the Epworth Sleepiness Scale (ESS).
  29. Depression determined by the Beck Depression Inventory (BDI-II) (unless previously diagnosed and well-controlled)
  30. Failure to use the smartphone app for documentation (defined as <2 meals/day for ≥3 days during baseline).

Sites / Locations

  • Altman Clinical and Translational Research InstituteRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Time restricted eating

Arm Description

Everyone in this arm will implement a daily 8-10-hour window within which they must consume their calories. They will also be required to log their caloric intake through the use of a smartphone app.

Outcomes

Primary Outcome Measures

Conduct a pilot clinical trial with POTS patients to assess if TRE can improve Quality of Life.
Intervention with TRE will significantly improve quality of life (QOL). We will conduct a 12-week intervention with POTS patients to assess the impact of TRE on QOL (primary endpoint) utilizing the quality of life questionnaire SF-36..

Secondary Outcome Measures

Full Information

First Posted
May 16, 2022
Last Updated
April 5, 2023
Sponsor
University of California, San Diego
Collaborators
Dysautonomia International
search

1. Study Identification

Unique Protocol Identification Number
NCT05409651
Brief Title
Phenotyping Mitochondrial and Immune Dysfunction in POTS With Targeted Clinical Intervention.
Official Title
Phenotyping Mitochondrial and Immune Dysfunction in POTS With Targeted Clinical Intervention.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 1, 2022 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, San Diego
Collaborators
Dysautonomia International

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The mechanisms underlying POTS are not well understood. Though heterogeneous in nature, patients often present with symptoms that include fatigue, orthostatic lightheadedness and tachycardia, "brain fog", shortness of breath, and sleep disruption. The central mediator that links observations in disease entities similar to POTS is energy use and balance driven by mitochondrial health. Mitochondrial dysfunction (i.e. respiration defects, reactive oxygen species (ROS) generation, and structural abnormalities) are hallmarks of currently defined syndromes that resemble POTS symptomatology. Many patients with POTS have underlying immune system dysfunction, which, when treated, may improve the patient's overall health. Though autoimmunity has been demonstrated in POTS, overall immune dysregulation may be broader and include immune cell exhaustion and persistent inflammatory cytokine responses. Immune dysfunction including cellular exhaustion and persistent inflammation has been linked to mitochondrial function. Therefore, we hypothesize that a unifying feature of POTS results from latent or continued mitochondrial/immune dysfunction which then impacts multi-organ energy imbalance and immune homeostasis. Understanding and targeting mitochondria utilizing established, novel, and directed approaches including time-restricted eating (TRE) will help to unravel common etiologies and help us to better diagnose, manage, and treat POTS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postural Tachycardia Syndrome
Keywords
Time-Restricted Eating, Intermittent fasting, POTS, Postural Tachycardia Syndrome

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Time restricted eating
Arm Type
Experimental
Arm Description
Everyone in this arm will implement a daily 8-10-hour window within which they must consume their calories. They will also be required to log their caloric intake through the use of a smartphone app.
Intervention Type
Behavioral
Intervention Name(s)
Time restricted eating
Other Intervention Name(s)
TRE
Intervention Description
Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study.
Primary Outcome Measure Information:
Title
Conduct a pilot clinical trial with POTS patients to assess if TRE can improve Quality of Life.
Description
Intervention with TRE will significantly improve quality of life (QOL). We will conduct a 12-week intervention with POTS patients to assess the impact of TRE on QOL (primary endpoint) utilizing the quality of life questionnaire SF-36..
Time Frame
Change from Baseline quality of life questionnaire at 14 weeks
Other Pre-specified Outcome Measures:
Title
Exploratory Outcome: Characterize mitochondrial function in POTS patients
Description
Mitochondrial damage is a common feature of POTS regardless of triggers, comorbidities, and heterogeneity. We will test this hypothesis by assessing blood-based markers of mitochondrial function in patients with POTS and compare to banked healthy controls.
Time Frame
Change from Baseline mitochondrial function at 14 weeks
Title
Exploratory Outcome: Assess whether POTS patients demonstrate persistent inflammatory responses and immune cell exhaustion
Description
Immune homeostasis is disrupted in POTS leading to aberrant persistent cytokine responses and immune cell (T, B, NK cell) exhaustion. We will test immune exhaustion and persistent inflammation through flow cytometry of peripheral blood cells from patients with POTS as well as perform serum multiplex ELISA of cytokines and compare them with banked controls.
Time Frame
Change from Baseline immune response at 14 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age: 18-70 years old BMI < 40 kg/m2 AND POTS, as defined by the presence of any of the following criteria: For patients age 20 or older, increase in heart rate ≥ 30 bpm within ten minutes of upright posture (tilt test or standing) from a supine position (For patients age 18-19, heart rate increase must be >40 bpm) Associated with related symptoms that are worse with upright posture and that improve with recumbency Chronic symptoms that have lasted for longer than six months In the absence of other disorders, medications, or functional states that are known to predispose to orthostatic tachycardia Baseline eating period > 12-hour window Exclusion Criteria: Taking insulin within the last 6 months. Manifest diabetes, defined as HbA1c > 7.0% given a 0.3% margin of error in lab readings, or diagnosis of diabetes. Known inflammatory and/or rheumatologic disease. Active tobacco abuse or illicit drug use or history of treatment for alcohol abuse. Pregnant or breast-feeding women. Shift workers with variable (e.g. nocturnal) hours. Caregivers for dependents requiring frequent nocturnal care/sleep interruptions. Planned travel to a time zone with greater than a 3-hour difference during study period. History of a major adverse cardiovascular event within the past 1 year (acute coronary syndrome (ACS), percutaneous coronary intervention, coronary artery bypass graft surgery, hospitalization for congestive heart failure, stroke/transient ischemic attack (TIA)). Uncontrolled arrhythmia (i.e. rate-controlled atrial fibrillation/atrial flutter are not exclusion criteria). History of thyroid disease requiring dose titration of thyroid replacement medication(s) within the past 3 months (i.e. hypothyroidism on a stable dose of thyroid replacement therapy is not an exclusion). History of adrenal disease. History of malignancy undergoing active treatment, except non-melanoma skin cancer. Known history of type I diabetes. History of eating disorder. History of cirrhosis. History of stage 4 or 5 chronic kidney disease or requiring dialysis. History of HIV/AIDS. Currently enrolled in a weight-loss or weight-management program. On a special or prescribed diet for other reasons (e.g. Celiac disease). Currently taking any medication that is meant for, or has known effect on, appetite. Any history of surgical intervention for weight management. Uncontrolled psychiatric disorder (including history of hospitalization for psychiatric illness). A score of >16 on the Epworth Sleepiness Scale (ESS). Depression determined by the Beck Depression Inventory (BDI-II) (unless previously diagnosed and well-controlled) Failure to use the smartphone app for documentation (defined as <2 meals/day for ≥3 days during baseline).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marissa Dzotsi, BA
Phone
858-534-8234
Email
preventiveCVresearch@health.ucsd.edu
First Name & Middle Initial & Last Name or Official Title & Degree
David Van, BS
Phone
858-246-2342
Email
preventiveCVresearch@health.ucsd.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pam Taub, MD
Organizational Affiliation
Professor of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Taylor Doherty, MD
Organizational Affiliation
Professor of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Altman Clinical and Translational Research Institute
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Justina P Nguyen, BS
Phone
858-246-2406
Email
preventivecvresearch@health.ucsd.edu
First Name & Middle Initial & Last Name & Degree
David T Van, BS
Phone
858-246-2342
First Name & Middle Initial & Last Name & Degree
Pam R Taub, MD

12. IPD Sharing Statement

Learn more about this trial

Phenotyping Mitochondrial and Immune Dysfunction in POTS With Targeted Clinical Intervention.

We'll reach out to this number within 24 hrs